Fibromyalgia Pipeline Review H2 2017 report provides key pharmaceutical companies, universities, and research institutes involved in Fibromyalgia therapeutics and drugs development and latest update related to Fibromyalgia. Fibromyalgia Pipeline drug profiles are analysed in this report. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 2, 5, 3 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecule, respectively. Report provides comprehensive information on the therapeutics under development for Fibromyalgia (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
Get Discount on Report http://www.reportsnreports.com/contacts/discount.aspx?name=1125811
Key Companies involved in Fibromyalgia Pipeline development Analyzed In report are Astellas Pharma Inc, Daiichi Sankyo Company Ltd, Immune Therapeutics Inc, Innovative Med Concepts LLC, Intec Pharma ltd, Jiangsu Hengrui Medicine Co Ltd, KPI Therapeutics Inc, Merck & Co Inc, Pfizer Inc, Switch Biotech LLC, Zynerba Pharmaceuticals Inc.The Fibromyalgia (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Fibromyalgia and features dormant and discontinued projects. Fibromyalgia (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Purchase This Report with 106 Pages including company profiles and pipeline drugs analysis at http://www.reportsnreports.com/purchase.aspx?name=1125811 .
The pipeline guide provides a snapshot of the global therapeutic landscape of Fibromyalgia (Gastrointestinal) and reviews pipeline therapeutics for Fibromyalgia (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources. Report covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages and features descriptive drug profiles for the pipeline products which comprise product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
Report reviews key companies involved in Fibromyalgia (Gastrointestinal) therapeutics and enlist all their major and minor projects and evaluate Fibromyalgia (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
Cognitive Impairment Associated with Fibromyalgia Drug Profile Analyzed are (cannabidiol + dronabinol), (celecoxib + famciclovir), AS-1069562, ASP-0819, ASP-8062, mirogabalin besylate, mirtazapine ODT, naltrexone hydrochloride, Peptide to Block Voltage-Dependent N-Type Calcium Channel for Central Nervous System, pregabalin CR, pregabalin SR, SWT-06101, U-2902, ZYN-001.
List of Tables:
- Number of Products under Development for Fibromyalgia, H2 2017
- Number of Products under Development by Companies, H2 2017
- Number of Products under Development by Universities/Institutes, H2 2017
- Products under Development by Companies, H2 2017
- Products under Development by Universities/Institutes, H2 2017
- Number of Products by Stage and Target, H2 2017
- Number of Products by Stage and Mechanism of Action, H2 2017
- Number of Products by Stage and Route of Administration, H2 2017
- Number of Products by Stage and Molecule Type, H2 2017
- Fibromyalgia – Pipeline by Astellas Pharma Inc, H2 2017
- Fibromyalgia – Pipeline by Daiichi Sankyo Company Ltd, H2 2017
- Fibromyalgia – Pipeline by Immune Therapeutics Inc, H2 2017
- Fibromyalgia – Pipeline by Innovative Med Concepts LLC, H2 2017
- Fibromyalgia – Pipeline by Intec Pharma ltd, H2 2017
- Fibromyalgia – Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2017
- Fibromyalgia – Pipeline by KPI Therapeutics Inc, H2 2017
- Fibromyalgia – Pipeline by Merck & Co Inc, H2 2017
- Fibromyalgia – Pipeline by Pfizer Inc, H2 2017
- Fibromyalgia – Pipeline by Switch Biotech LLC, H2 2017
- Fibromyalgia – Pipeline by Zynerba Pharmaceuticals Inc, H2 2017
- Fibromyalgia – Dormant Projects, H2 2017
- Fibromyalgia – Dormant Projects, H2 2017 (Contd..1), H2 2017
- Fibromyalgia – Discontinued Products, H2 2017
Reportsnreports.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.
2nd Floor, Metropole,
Bund Garden Road,
Pune – 411001,
Tel: + 1 888 391 5441